This application note shows how Sievers TOC analyzers and common sensors in the industry recover 11 different compounds most often used in water and product analysis.
Developing bioassay methods requires a new approach for cell and gene therapy drug development.
E&L analytical testing methods can be determined through pointed consideration of the differences small- and large-molecule drug products.
Hot Melt Extrusion (HME) is a widely utilized pharmaceutical technique designed to enhance the bioavailability of poorly soluble drugs through solid molecular dispersions. Effective analytical characterization plays a critical role in the efficient development of HME formulations.
Many biologic drug manufacturers encounter similiar challenges; precompetitive collaboration can help resolve these issues. Representatives of the IQ Consortium’s Biologics CMC Leadership Group describe efforts to address the safe handling of biologic drugs in closed-system transfer devices in healthcare settings and the need for phase-appropriate specifications.
Proper selection of normal flow filters leads to increased process efficiency from early phase product development through to full-scale biopharmaceutical production.
Testing the dissolution rates of a pharmaceutical formulation (also known as in vitro availability) aids drug quality control and is a compulsory requirement of the British, European and US pharmacopoeias.
The authors examine the effectiveness of an excipient comprised of mannitol, polyvinyl acetate, and crospovidone using model actives loperamide hydrogen chloride and caffeine.
Although tablet manufacture is traditionally a batchbased wet granulation process, there are many advantages to be gained by adopting dry granulation, including lower costs and increased yields.
Webinar Date/Time: Tue, Sep 24, 2024 10:00 AM EDT 7am PDT | 3pm BST | 4pm CEST
In this final part of a series of three articles, the results from experiments involving cohesive materials are discussed in terms of mixing performance, agglomerate comminution, and lubrication of powder mixtures.
A data-integrity risk assessment tool has been developed for use with standalone R&D data-acquisition and processing software.
Stringent patentability requirements present a challenge to obtaining broad-based antibody claims, so companies should develop a strategy based on multiple reinforcing layers of protection.
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
Sponsors should consider best practices for maintaining data generated during sample analysis and instrument maintenance.
A recent book shows the links between synthesis, catalysis, and environmental protection.
ICH Q6B provides expectations and a clear framework for the structural characterization of biopharmaceutical products.
The scaled adoption of cell and gene therapies demands a new era of agile, precise, and efficient quality control methods. Manufacturers and diagnostic partners must collaborate to create innovative, compliant testing strategies that preserve product integrity, meet tight timelines, and deliver life-saving treatments faster.
This position paper describes a model for the future that would provide appropriate standardization, facilitate drug registration and support regulatory agencies.
Webinar Date/Time: Thu, Jul 20, 2023 11:00 AM EDT
The most important consideration when choosing a freeze dryer is to ensure the system is fit for both today's applications and future needs.
Creating an inhaled formulation is one way in which improved efficacy or added value can be achieved in projects to repurpose or reposition existing drugs.
Assessing biosafety using NGS-based tests requires a continuum of skills in molecular biology, biocomputing, virology, and quality systems.
Investigators are exploiting the tremendous structural diversity of polypeptides and their biophysical properties to develop novel drug carriers. Peptide-based materials hold out much promise for tailor-made targeting, penetration, and release of contents in a host of biological microenvironments.
Analytical procedure performance can be continually verified by risk-based monitoring of performance related data.
Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.